Redeye provides an update following the Q1 2024 report.
Sales -6% vs. cons, adj. EBIT -18% vs. cons Drop in utilisation lowered sales by ~9% y-o-y alone Mar...
Redeye will likely increase its forecasts and Base Case following a strong Q1 report driven by a sig...
Redeye updates on Evolution post Q1-results which came in slightly stronger than our forecast, albei...
Sales +11%, adj. EBITA +16% vs. cons, +8% org. sales Cons to raise '24e adj.
Förvaltningsresultat ökade med 17% på årsbasis drivet av främst ränteintäkter.
Scanfil's Q1 net sales and clean EBIT were below LSEG Data & Analytics consensus.
Føroya Banki (previously BankNordik) will publish its Q1 2024 report on 2 May.
Redeye updates its estimates and valuation following Lifco releasing its Q1 2024 report, which came ...
Redeye is making some downward adjustments to our financial forecasts following the Q1 report.
We raise adj. EBITA by 2-1-0% on '24e-'26e Adj. EBITA expected to grow 12% y-o-y in H2'24e 10-8x EBI...
'24e-'26e sales up 2-1% Volume growth to continue into the year FVR of SEK 20-35 reiterated Q1: Str...
Strong y-o-y growth: EEs +18%, SCs +36%, sales +22% EBIT margin 23% (25%), ~33% adjusted for FX effe...
Tough comps, we expect -3% org sales growth (119% Q1'23) The Intercom order behind 2024e estimate ch...
Rec. PTP -6% vs ABGSCe Sector-low LTV leaves room to grow Limited revisions, all eyes on CMD in 3w ...
Tumorad is in clinical phase 1, and today, Spago Nanomedical announced that Tumorad had promising re...
- Geographical diversity gives resilience - UK grew 6% org.
Redeye comments on Truecaller’s newly proposed dividend policy, which we believe de-risks the case w...
Efter att rekordordern som togs i det förra kvartalet levererats har Aixia ingått flertalet nya och ...
XVIVO improved its organic growth to 32% compared with the unusually modest 12% level in Q4 2023.
